Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations

BACKGROUND: Despite the remarkable advances in the early diagnosis and treatment, overall 5-year survival rate of patients with pancreatic cancer is less than 10%. Gemcitabine (GEM), a cytidine nucleoside analogue and ribonucleotide reductase inhibitor, is a primary option for patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Toshinori, Yu, Meng, Yin, Danjing, Sun, Dan, Zhu, Yuyan, Bu, Youquan, Sang, Meixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861661/
https://www.ncbi.nlm.nih.gov/pubmed/29558908
http://dx.doi.org/10.1186/s12885-018-4217-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861661/
https://www.ncbi.nlm.nih.gov/pubmed/29558908
http://dx.doi.org/10.1186/s12885-018-4217-9

Ejemplares similares